2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, (CAR)-T Cell Therapies, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Adverse Events, Biological Processes, Apoptosis, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Research, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1524 Clinical Characteristics and Outcomes of Adults with Low Hypodiploid B-Cell Acute Lymphoblastic Leukemia

Hannah Goulart, MD, Hagop Kantarjian, MD2, Guilin Tang, MD, PhD,FACMG3, Nitin Jain, MD4, Tapan Kadia I, MD5, Farhad Ravandi, MD6, Rebecca Garris7, Guillermo Garcia-Manero, MD8, Nicholas Short, MD9, Elias Jabbour, MD10
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: Low hypodiploidy (31-39 chromosomes, HoDi) B-cell acute lymphoblastic leukemia (B-ALL), including “masked” hypodiploid cases with a near triploid chromosome number, is a rare and high-risk genomic subtype associated with TP53 mutations, chemoresistance, and poor long-term outcomes. Because of its rarity, the optimal management of patients (pts) with HoDi B-ALL remain poorly defined. Therefore, we analyzed our cohort of adults with newly diagnosed HoDi B-ALL to assess their clinical course and outcomes.

Methods

We retrospectively analyzed a cohort of 490 adult pts with newly diagnosed B-cell ALL treated at our institution from November 2002-May 2026 to determine the incidence of HoDi B-ALL. Clinical, cytomolecular, treatment responses including measurable residual disease (MRD), and survival outcomes were assessed. Overall survival (OS) and event-free survival (EFS) were estimated using the Kaplan-Meier method, while relapse and non-relapse mortality were analyzed using competing risks methods.

Results

Thirty-one pts (6%) were identified as having HoDi B-ALL. The median age was 53 years old (range, 18 – 81 years old); 10 pts (32%) > 60 years of age. Seventeen pts (54%) were male, and most pts were white (n = 22, 71%), with an equal distribution of Non-Hispanic (n = 13, 42%) and Hispanic (n = 12, 39%) pts. 26/27 (96.3%) pts  had concurrent TP53 mutations, with a median variant allele frequency of 66% (4 – 89), with 3 pts harboring two mutations in TP53.

A total of 8 pts (26%) received Hyper-CVAD in combination with either rituximab or ofatumumab; the remaining 23 pts (74%) received blinatumomab (blina)-containing regimens: Hyper-CVAD blina with or without inotuzumab ozogamicin (InO), (n = 9, 29%), mini-CVD Blina +/- InO (n = 7, 23%), InO/Blina (n = 7, 23%); a total of 17 pts (23%) received InO in combination with Blina.

The overall response rate was 97%; only 1 pt did not respond. Best response was achieved after 1 cycle in the majority pts (30/31, 97%). A total of 23 of 28 evaluable pts (82%) achieved measurable residual disease (MRD)-negativity by multiparameter flow cytometry (FCM). MRD-negativity by next-generation sequencing (NGS) was achieved in 1 of 4 evaluable pts (25%).

The median follow-up time for the entire cohort was 21 months (95% CI 11.7 – 71.6 months). Neither the median EFS nor OS were reached. The estimated 2-year EFS rate was 65%, with an estimated 2-year OS rate of 73%. With death and relapse as competing risks, the 2-year cumulative incidence of relapse was 26% with a non-relapse mortality rate of 7%. Pts >60 years had significantly inferior survival, with a 2-year OS rates of 37% compared to 88% in those <60 years (p = 0.025). Similarly, those with TP53 VAF >50% had significantly inferior OS compared to those with lower VAF (2-year OS rates of 48% versus 93%, respectively, p = 0.058)

A landmark analysis at 6 months demonstrated an estimated 2-year OS rate of 85% versus 72% for pts that did versus did not proceed to allogeneic hematopoietic stem cell transplant (allo-HSCT), respectively (p = 0.51). Multivariable analysis incorporating age, allo-HSCT as a time dependent factor, and receipt of blinatumomab demonstrated that increasing age was associated with a significant trend towards inferior OS (HR 2.22, 95% CI 0.97-5.08, p = 0.05), while blinatumomab exposure (HR 1.57 95% CI 0.15-16, p = 0.71) and receipt of allo-HSCT (HR 0.93, 95% CI 0.09-9.19, p = 0.95) were not independently associated with OS.

Eight pts (26%) underwent allo-HSCT in first complete remission (CR1), of which 1 (12%) has relapsed and died, with the remaining 7 pts (88%) alive in CR. Of the 23 pts (74%) who did not proceed to allo-HSCT, 6 (26%) have relapsed of which 4 died, 3 (13%) died in CR (causes: n = 1 unknown, n = 1 sepsis/multiorgan failure, n = 1 hypoxemic respiratory failure), and 1 non-responding pt died of progressive disease. One pt proceeded to chimeric antigen receptor T-cell therapy and remains in CR, and 12 pts (52%) who did not proceed to allo-HSCT remain alive in CR.

Conclusion

HoDi B-ALL remains a rare and biologically aggressive subtype, enriched among older pts and characterized by frequent TP53 mutations. Despite high remission rates, relapses remain common and older age continues to adversely impact survival. Larger studies will be required to determine whether the integration of immunotherapy results in improved long-term outcomes. 

Hannah Goulart, MD: No relevant conflicts of interest to declare.